Zentalis Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.99 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 188.40M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Details
| Name | Zentalis Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 106 |
| Founded | 2014 |
| Ipo Date | 2020-04-03 |
| Ceo | Julie Eastland |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 18.00 |
| Isin | US98943L1070 |
| Cusip | 98943L107 |
| Cik | 1725160 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Julie M. Eastland M.B.A. | Chief Executive Officer, President and Director |
| James B. Bucher J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Ingmar Bruns M.D., Ph.D. | Chief Medical Officer |
| Vincent A. Vultaggio | SVice President of Finance and Principal Accounting Officer |
| Robert J. DiVasto P.E. | Chief Technical Officer |
| Wendy Chang | Chief People Officer |
| Haibo Wang | Chief Business Officer |
| Rajesh Israni | Executive Vice President of Regulatory Affairs and Medical Writing |
| Henry Gu | Senior Vice President and Head of Intellectual Property |
| Sarah Kelly | Senior Vice President of Commercial Strategy |
Contact
| Address | 10275 Science Center Dr., Suite 200, San Diego, California 92121, United States |
| Phone | 858 263 4333 |
| Website | https://zentalis.com |